Further support for the link between elevated Lp(a) and high risk plaque (HRP) features comes from two recently published studies using coronary computed tomography angiography (CCTA) and validated AI-based algorithms.1,2
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.